A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2016
At a glance
- Drugs Emricasan (Primary)
- Indications Liver cirrhosis; Liver failure
- Focus Pharmacokinetics
- Sponsors Conatus Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 08 Apr 2015 According to a Conatus Pharmaceuticals media release, detailed results from this trial will be presented in a late-breaker poster at The International Liver Congress 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL).
- 11 Mar 2015 According to a Conatus Pharmaceuticals media release, aggregate top-line results from this and two other phase I trials, (n=73) in five distinct organ impairment patient populations were released in Jan 2015.